RIGL - Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals is a commercial-stage biopharmaceutical company focused on hematology and oncology, with its primary marketed products being Tavalisse (fostamatinib), an oral spleen tyrosine kinase (SYK) inhibitor approved for chronic immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (AIHA), and Rezlidhia (olutasidenib), an IDH1 inhibitor for relapsed or refractory acute myeloid leukemia (AML). The business model is specialty pharma selling to hematologists and oncologists at hospitals and specialty clinics in the United States, with revenue generated from net product sales and licensing/royalty arrangements with partners. Annual revenue is in the range of $70–90M, primarily from U.S. commercial sales, with international rights licensed to partners in select markets. The company operates at a net loss as it funds ongoing clinical development while scaling its commercial hematology/oncology portfolio.

Past Year Trends

• Tavalisse (fostamatinib) net product sales grew 52% YoY to $158.8 million in full-year 2025, driven by increased adoption in immune thrombocytopenia and driving total company revenue up 64% to $294.3 million. (Bullish)
• Rigel settled Tavalisse patent litigation with Annora Pharma and Hetero Labs in 2025, granting generic entry rights starting mid-2032, locking in a near-term revenue runway but confirming a hard patent cliff. (Neutral)
• Net income surged to $367 million in 2025 versus $17.5 million in 2024, reflecting the company's first year of sustained profitability and a strengthened cash position rising from $77.3 million to $155.0 million by year-end 2025. (Bullish)

Next Year Trends

• Rigel acquired exclusive global rights to Veppanu (vepdegestrant), FDA-approved May 1, 2026 for ER+/HER2-/ESR1-mutated advanced breast cancer, paying $70 million upfront with up to $320 million in additional milestones, adding a new commercial product but concentrating near-term cash outflows. (Neutral)
• Eli Lilly terminated its RIPK1 inhibitor (R552/ocadusertib) collaboration effective June 15, 2026, eliminating future milestone payments from that program and returning full rights to Rigel with no guaranteed development path or partner funding. (Bearish)
• R289 (IRAK1/4 inhibitor) Phase 1b dose expansion in lower-risk MDS is enrolling up to 40 patients with recommended Phase 2 dose selection expected in H2 2026; early data showing 33% transfusion independence rate at ≥500 mg doses could serve as a key pipeline re-rating event. (Bullish)

Red Flags

No severe red flags identified as of August 2025.